Health Canada has announced that drugs for Attention Deficit Hyperactivity Disorder (ADHD) will come with stronger and clearer warnings on the risks of suicidal thoughts and behaviors.
According to the health agency, the new warnings are based on reports of suicidal thoughts, suicide attempts and in a very small number of cases, completed suicide.
The warning is already in place for one ADHD drug, Strattera (atomoxetine), which had the risk information added to its prescribing information.
"New information has emerged since to suggest that the risk of suicidal thoughts and behaviors may apply to all other ADHD drugs," Health Canada officials said.
They also said that there is little evidence to establish that these drugs cause suicidal thoughts, but it is possible that they may contribute to the risk.
"It is also important to note that people with ADHD may already have a slightly increased risk of suicidal thoughts and behaviours," officials added.